



ASX ANNOUNCEMENT

6 March, 2015

Results from 2015 Extraordinary General Meeting

Melbourne, Australia; 6 March 2015: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) advises that the 2015 Extraordinary General Meeting of shareholders was held at 10.00 am today (Melbourne time).

All four (4) resolutions that were put before the shareholders were passed on a show of hands. Details of the proxy votes received by the Company in respect of all four resolutions is contained in **Table 1** to this announcement on the attached page.

FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Eutillio Buccilli
Chief Executive Officer
Genetic Technologies Limited
+ 61 3 8412 7050

Candice Knoll (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 105

About Genetic Technologies Limited

Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product, BREVAGen*plus*®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGen*plus*® improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGen*plus*® expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.

The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGen*plus*®, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGen*plus*® to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).

For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the [Private Securities Litigation Reform Act](#). The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

Table 1 - Proxy results for 2015 Extraordinary General Meeting

| Description of Resolution | For | Against | Abstain | In favour of Chairman | In favour of others |
|--|---------------------|-----------------|-----------------|-----------------------|---------------------|
| 1. Ratification of prior Placement of Shares to Ironridge Global IV Ltd Numbers of votes received Percentage of votes cast | 19,152,206 47.5% | 698,745 1.7% | - 0.0% | 20,499,323 50.8% | - 0.0% |
| 2. Ratification of prior Placement of Shares to Kentgrove Capital Growth Fund Numbers of votes received Percentage of votes cast | 19,152,206 47.5% | 698,745 1.7% | - 0.0% | 20,499,323 50.8% | - 0.0% |
| 3. Standby Equity Placement Facility (Kentgrove Capital Growth Fund) Numbers of votes received Percentage of votes cast | 19,152,206 47.5% | 430,622 1.1% | 263,123 0.6% | 20,499,323 50.8% | - 0.0% |
| 4. Approval of proposed new placement of Shares to sophisticated investors Numbers of votes received Percentage of votes cast | 19,152,206 47.5% | 430,622 1.1% | 263,123 0.6% | 20,499,323 50.8% | - 0.0% |

Note: The Company currently has a total of **1,214,191,681** ordinary shares on issue and **3,164** registered shareholders.